Back to mobile site

Osiris Therapeutics (OSIR) Posts Q2 Loss of 11c/Share

August 5, 2013 9:04 AM EDT
Osiris Therapeutics (NASDAQ: OSIR) reported Q2 EPS of ($0.11), $0.02 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $5.29 million versus the consensus estimate of $4.35 million.

For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings